» Articles » PMID: 19790153

Risk Factors for Recurrence of Autoimmune Hepatitis After Liver Transplantation

Overview
Journal Liver Transpl
Date 2009 Oct 1
PMID 19790153
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune hepatitis has been reported to recur after liver transplantation. The aim of our study was to evaluate the risk factors associated with recurrence of autoimmune hepatitis. Forty-six patients that underwent liver transplantation because of end-stage liver disease secondary to autoimmune hepatitis were studied. Recurrence of autoimmune hepatitis was diagnosed in 11 of the 46 (24%) patients, and the overall 5-year probability of recurrence was 18%. By univariate Cox analysis, the features before liver transplantation associated with a higher risk of recurrence were concomitant autoimmune disease [hazard ratio (HR), 3.74; 95% confidence interval (CI), 1.05-13.36; P = 0.04], high aspartate aminotransferase (HR, 1.09; 95% CI, 1.03-1.14; P = 0.002), high alanine aminotransferase (HR, 1.09; 95% CI, 1.03-1.20; P = 0.003), and high immunoglobulin G (IgG; HR, 1.25; 95% CI, 1.11-1.41; P = 0.0003). Moreover, patients with recurrence had a higher frequency of moderate to severe inflammatory activity (HR, 5.3; 95% CI, 1.55-18.79; P = 0.008) and plasma cell infiltration in the liver explant (HR, 5.8; 95% CI, 1.52-22.43; P = 0.01). In the multivariate Cox analysis, only the presence of moderate to severe inflammation (HR, 6.9; 95% CI, 1.76-26.96; P = 0.006) and high IgG levels before liver transplantation (HR, 7.5; 95% CI, 1.45-38.45; P = 0.02) were independently associated with the risk of autoimmune hepatitis recurrence. In conclusion, patients with concomitant autoimmune disease, high aspartate aminotransferase, alanine aminotransferase, and IgG before the transplant, or moderate to severe inflammatory activity or plasma cell infiltration in the liver explant have a higher risk of recurrent disease. These findings suggest that recurrence of autoimmune hepatitis may reflect incomplete suppression of disease activity prior to liver transplantation.

Citing Articles

Liver Transplantation for Autoimmune Hepatitis: 20 Years of Tertiary Centre Experience.

Saglam O, Muhip Harputluoglu M, Bilgic Y, Yilmaz S, Yagin F, Efe C Turk J Gastroenterol. 2024; 1(1).

PMID: 39696995 PMC: 11899994. DOI: 10.5152/tjg.2024.24464.


Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention.

Mehtani R, Rathi S J Clin Exp Hepatol. 2024; 14(6):101432.

PMID: 38975605 PMC: 11222954. DOI: 10.1016/j.jceh.2024.101432.


Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.

Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J Hepatol Int. 2024; 18(2):299-383.

PMID: 38416312 DOI: 10.1007/s12072-023-10629-3.


Post-Transplant Management and Complications of Autoimmune Hepatitis, Primary Biliary Cholangitis, and Primary Sclerosing Cholangitis including Disease Recurrence.

Henson J, King L Clin Liver Dis. 2023; 28(1):193-207.

PMID: 37945160 PMC: 11033708. DOI: 10.1016/j.cld.2023.07.009.


Sex differences in chronic liver disease and benign liver lesions.

Cooper K, Delk M, Devuni D, Sarkar M JHEP Rep. 2023; 5(11):100870.

PMID: 37791378 PMC: 10542645. DOI: 10.1016/j.jhepr.2023.100870.